|
Futibatinib Clinical Trials
6 actively recruiting trials across 2 locations
▲ +1 trial since July 2026
Also known as: Lytgobi, TAS-120, Tas-120
Pipeline
Phase 2: 3Phase 3: 2Phase 1/2: 1
Top Sponsors
- Yuanquan Yang1
- Vall d'Hebron Institute of Oncology1
- UNICANCER1
- Taiho Pharmaceutical Co., Ltd.1
- Gustave Roussy, Cancer Campus, Grand Paris1
Indications
- Cancer6
- Stage IIIA Bladder Cancer AJCC v81
- Stage II Bladder Cancer AJCC v81
- Bladder Urothelial Carcinoma1
- Biliary Tract Neoplasms1
Other4 trials
Birmingham, Alabama1 trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
University of Alabama at Birmingham Comprehensive Cancer Center
Phase 2
Ann Arbor, Michigan1 trial
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
University of Michigan Comprehensive Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.